



Indicated for  
**Aneurysm**  
**Type B Dissection**  
**Transection**

**Pioneering TEVAR therapy,  
time and time again**



THORACIC  
ENDOPROSTHESIS

## Time-tested success

For more than **20 years**, the GORE® TAG® Device family has demonstrated impressive success in both clinical studies and real-world commercial use.

### More than **125,000 devices** distributed worldwide

For more than two decades, we have worked alongside physicians in the evolution of the GORE® TAG® Device family. Our collaboration has resulted in the distribution of more than 125,000 devices, for the treatment of more than **73,500 patients** worldwide.<sup>1</sup>

### Proven clinical results

The GORE® TAG® Device family is supported by more than **20 years** of clinical experience.

### Most studied thoracic endograft available

With the first clinical implant occurring in 1998, the GORE® TAG® Device family has been studied in **ten FDA approved clinical studies**, one European clinical trial (ADSORB), and one worldwide registry (GREAT).

### Forty years of experience with ePTFE graft material

Having pioneered ePTFE graft technology more than **40 years** ago, Gore continues to collaborate with physicians and scientists to create a robust and reliable design platform based on proven clinical performance.

1. Data on file

**1998**

**FIRST** thoracic stent graft to receive CE Mark in Europe

**2005**

**FIRST** thoracic stent graft approved in U.S.

**2008**

**FIRST** thoracic stent graft approved in Japan

**2012**

**FIRST** thoracic stent graft approved in U.S. for isolated lesions including traumatic transections\*

**2013**

**FIRST** thoracic stent graft approved in U.S. for aneurysms, transections, *and* acute and chronic Type B Dissections

**2016**

**FIRST** TEVAR device to reach 100,000 devices distributed worldwide



\* Conformable GORE® TAG® Device was approved in U.S. for DTA aneurysms in 2011.




# Conformable GORE® TAG® Device is *conformability without compromise*

## Designed to treat compromised aortas

- 1 No bare springs or barbs
- 2 Designed with optimal radial force to decrease the risk of intimal damage

## Highly conformable to accommodate natural anatomy

- 3 Optimized graft construct to maximize device durability and conformability
- 4 Partially uncovered stents maximize circumferential wall apposition to aid in sealing of the primary entry tear and depressurization of the false lumen while not compromising aortic blood flow
- 5 Fully covered distal end provides a transition between the stent frame and the septum, decreasing the risk of septum perforation



## Able to treat more patients

- Small diameter and tapered devices offer a large treatment range
- Broad 6 – 33% oversizing windows allow physicians to choose device with the optimal radial fit for patient anatomy
- Larger device oversizing windows engineered, tested, and proven to accommodate differences in proximal and distal landing zone diameters



## Flexible delivery system tracks in challenging anatomy

- Soft leading catheter tip for navigation through tortuous and fragile dissection anatomy
- Easy one-step deployment



## Proven compression resistance

- No reports of compression with more than 110,000 devices distributed worldwide\*
- Increased wire diameter optimizes radial force to resist compression in high flow aortas
- Nine apex stent pattern further distributes point load and contributes to long-term durability in maximum oversizing conditions
- Unique sutureless design and stent graft construction facilitates consistent conformability throughout the device for uniform arch support

\* W. L. Gore & Associates, Inc. *GORE® TAG® Thoracic Endoprosthesis Annual Clinical Update*. Flagstaff, AZ: W. L. Gore & Associates, Inc; 2016. AS0089-EN3.

**With the FDA approved indication for acute and chronic Type B dissections, Conformable GORE® TAG® Device is the *first thoracic stent graft* approved to treat aneurysms, transections, and Type B dissections.**

For more than two decades, we have worked closely with physicians to evolve TEVAR therapies and improve patient outcomes. That's why today, Conformable GORE® TAG® Device is still a leading less-invasive treatment option.

Engineered for flexibility in tortuous anatomy, the Conformable GORE® TAG® Device provides enhanced conformability to treat the challenges associated with dissected aortas.



**W. L. GORE & ASSOCIATES, INC.**

Flagstaff, AZ 86004

+65.67332882 (Asia Pacific)

00800.6334.4673 (Europe)

800.437.8181 (United States)

928.779.2771 (United States)

**[goremedical.com](http://goremedical.com)**

**INDICATIONS FOR USE IN THE US:** The GORE® TAG® Thoracic Endoprosthesis is intended for endovascular repair of all lesions of the descending thoracic aorta, including: Isolated lesions in patients who have appropriate anatomy, including: adequate iliac / femoral access, aortic inner diameter in the range of 16–42 mm,  $\geq 20$  mm non-aneurysmal aorta proximal and distal to the lesion; Type B dissections in patients who have appropriate anatomy, including: adequate iliac / femoral access,  $\geq 20$  mm landing zone proximal to the primary entry tear; proximal extent of the landing zone must not be dissected, diameter at proximal extent of proximal landing zone in the range of 16–42 mm. **INDICATIONS FOR USE UNDER CE MARK:** The GORE® TAG® Thoracic Endoprosthesis is indicated for endovascular repair of the descending thoracic aorta. **CONTRAINDICATIONS:** Patients with known sensitivities or allergies to the device materials; patients with a systemic infection who may be at increased risk of endovascular graft infection. Refer to *Instructions for Use* at [goremedical.com](http://goremedical.com) for a complete description of all warnings, precautions, and adverse events.  $\text{K}_017$

Products listed may not be available in all markets.

GORE®, TAG®, and designs are trademarks of W. L. Gore & Associates.

© 2014, 2018 W. L. Gore & Associates, Inc. AT1141-EN3 APRIL 2018